199 results about "Endometrioses" patented technology

The invention discloses a kit and application thereof, the kit comprises a detection reagent for detecting the expression quantity of one or more RNA molecules, and accurate diagnosis of endometriosis can be realized. In addition, the invention also discloses a method for diagnosing the endometriosis.

The invention relates to the technical field of image recognition, in particular to an adhesion focus positioning method for an endometriosis rat model, which comprises the following steps of: firstly, adjusting a clustering distance according to color difference between saturation connected domains and a position inertial system, and clustering to obtain a connected domain cluster; due to the fact that the connected domain clusters contain the ectopic glands, the clusters need to be screened to obtain the ectopic glands, the gland probability of each connected domain cluster is obtained according to the characteristic that columnar epithelial cells are distributed on the inner walls of the ectopic glands, and the possibility that each connected domain cluster belongs to the ectopic glands is judged; due to the fact that the ectopic glands are distributed in a concentrated mode, the abnormal probability of the connected domain clusters is obtained through the aggregation of the connected domain clusters with the high gland probability, the possibility that the connected domain clusters belong to the abnormal ectopic glands is further judged, and the focus positioning accuracy of the endometriosis rat model is higher.

The invention discloses a multi-modal image auxiliary diagnosis system based on endometriosis and a medium. The system comprises a determination module, a diagnosis module and a diagnosis module, wherein the determination module is used for determining focus position information, a metabolic activity analysis result and hemodynamic characteristic data according to a near infrared spectrum image, a magnetic resonance image and an ultrasonic image of a human body; the extraction module is used for extracting lesion feature information from different modal images; the optimization and reconstruction module generates a focus multi-modal image according to the focus feature information, processes the focus multi-modal image to obtain a focus three-dimensional model, and obtains a focus morphological feature quantized value based on the focus three-dimensional model; and the diagnosis module inputs the medical record related information, the focus morphological characteristic quantized value, the metabolic activity analysis result and the hemodynamic characteristic data into a preset focus comprehensive diagnosis model, and outputs a diagnosis result of endometriosis. According to the method, the multidimensional information is analyzed through the preset focus comprehensive diagnosis model, and accurate diagnosis of endometriosis is realized.

A use of a GPR1 as a target in preparing an endometriosis-related diagnostic and / or therapeutic formulation, relating to the technical field of biomedicine. The present invention provides a use of a GPR1 target as a diagnostic marker in preparing a reagent or kit for diagnosing endometriosis. The endometriosis is selected from one of uterosacral ligament endometriosis, peritoneal endometriosis, rectovaginal endometriosis, deep infiltrating endometriosis, and ovarian endometriosis. The present invention discovers that the expression of the GPR1 is significantly increased in endometriosis tissues and cells, indicating that the GPR1 can be used as a diagnostic marker for endometriosis. It has been discovered in in-vitro and in-vivo models that GPR1 knockout significantly inhibits the abilities of hEM15A cells to proliferate, migrate, and invade and the growth of ectopic foci in animals, indicating that the GPR1 can be used as a new intervention target for clinically treating endometriosis.

The invention belongs to the field of biological medicines, and finds and verifies that taquinimod or pharmaceutically acceptable salts thereof can be used for preparing medicines for treating endometriosis for the first time, and is particularly suitable for progestogen-resistant, recurrent or deep infiltration type endometriosis. The action mechanism of the taquinimod is as follows: the taquinimod can down-regulate the expression of S100A9 protein and reduce the infiltration of S100A9 + macrophages by inhibiting an NF-kappa B signal channel so as to further inhibit the expression of a vascular endothelial growth factor receptor 1 (VEGFR1) and a matrix metalloproteinase 2 (MMP2), finally block pathological angiogenesis and inhibit the growth of ectopic lesions. Animal experiments show that the taquinimod can significantly reduce the number and weight of nidus of a mouse model with endometriosis. The invention provides a brand-new non-hormone treatment choice with a clear action mechanism for clinical application, provides a pharmaceutical composition containing a specific dosage and a drug combination scheme, and has an important clinical value.

Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof: wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; r3'and R3 ''independently represent a hydrogen atom, a methyl group, a methoxyl group, a chlorine atom, a fluorine atom, or a cyano group; r4 represents a hydrogen atom or a fluorine atom; r5 and R5'independently represent a hydrogen atom or a fluorine atom; y represents-CH2-,-CH =,-CR9 =,-O-or-NH-wherein R9 represents a fluorine atom or a (C1-C3) alkyl group; represents a single bond or a double bond; p is 0 or 1; x represents-CH =,-N = or-CR ''= wherein R'' represents a (C1-C3) alkyl or halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; r7 independently represents a (C1-C3) alkyl group, a halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; n is 0, 1 or 2; and R6 represents a (C1-C6) alkyl group, said alkyl group being optionally substituted; r8 represents a hydrogen atom, a (C1-C3) alkyl group, a-CH2F group, a-CHF2 group, a-CF3 group, or a (C3-C4) cycloalkyl group. Further disclosed are processes for preparing the same, pharmaceutical compositions comprising the same and the compounds of formula (I) for use as inhibitors and degrading agents of estrogen receptors, in particular for use in the treatment of ovulation dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hyperplasia or inflammation. # imgabs0 #

The present invention relates to methods for treating endometriosis or preventing recurrence of endometriosis. In particular, the present invention relates to methods for treating endometriosis and recurrence thereof comprising administering to a female having endometriosis a pharmaceutical composition comprising an S-alkylisothiouronium derivative, specifically S-ethylisothiouronium diethylphosphate. The methods and pharmaceutical composition of the present invention preserve fertility and enable conception.

The invention discloses application of GPR1 as a target spot in preparation of endometriosis related diagnosis and / or treatment preparations, and belongs to the technical field of biological medicines. The invention provides application of a GPR1 target spot serving as a diagnostic marker in preparation of a reagent or a kit for diagnosing endometriosis. The endometriosis is selected from one of a uterus-sacral ligament type endometriosis, a peritoneal type endometriosis, a rectum-vagina type endometriosis, a deep infiltration type endometriosis and an ovarian type endometriosis. The invention discovers that the expression of GPR1 in endometriosis tissues and cells is obviously increased, which prompts that GPR1 can be used as a diagnostic marker of endometriosis. In-vitro and in-vivo models find that the knockout of GPR1 significantly inhibits the proliferation, migration and invasion ability of hEM15A cells and the growth of ectopic lesions in animals, indicating that GPR1 can be used as a new intervention target for clinical treatment of endometriosis.

Provided herein is a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, and a formulation comprising the same, for use in the treatment or prevention of endometriosis.

The present invention relates to a composition comprising Eptinezumab and LuAG09222. The composition can be used for treating or preventing e.g., headache, pain, migraine, cluster headache or endometriosis.

Provided is a method and a medicament for treating endometriosis in a subject in need thereof, comprising administering to the subject an effective amount of an Integrin Subunit Beta 2 antagonist.

The invention discloses a construction method of a novel ovarian endometriosis mouse model. Longitudinally cutting the uterus tissue of the donor mouse into small pieces; then putting the small uterus blocks into a collagenase solution for incubation; then removing collagenase from the small uterus blocks; attaching the small uterus block to the notch of the female mouse of which the envelope on the ovary surface is cut, so that the small uterus block covers the exposed ovary surface, pushing back into the abdominal cavity as soon as possible, nailing the skin and muscles by using a suturing nail, disinfecting and putting back into the mouse cage; after 24 hours of fasting, water can be freely drunk; and conventionally feeding after 24 hours. The method does not need preoperative / postoperative estradiol management, has the advantages of simplicity in operation, time saving, good effect, high molding success rate (about 90%) and the like, and is worthy of further popularization. The constructed ovarian endometriosis mouse model can evaluate the ovarian function condition and the influence of infertility, and overcomes the defect that the existing endometriosis mouse model lacks special ovarian types.

This invention relates to the field of medical information management technology, including an AI-based endometriosis management system. The system comprises a thickness dynamic monitoring module, an inflammation level assessment module, a lesion spread analysis module, a periodic lesion tracking module, and a disease progression analysis module. In this invention, AI is used to segment ultrasound image data, enabling dynamic monitoring of lesion areas. Lesion boundaries are extracted, and changes in local inflammatory marker concentrations are calculated, making the screening of abnormal inflammatory areas more accurate and enabling early identification of lesion development. The tracking of periodic lesions, combined with analysis of lesion contour changes and area increases / decreases, enhances the quantitative control of disease progression. The future development trend of lesions, combined with the calculation of periodic inflammatory pathways, makes the prediction of disease evolution more consistent with physiological changes. Multi-dimensional lesion analysis combined with AI intelligent calculation expands the diagnosis and treatment of endometriosis from static assessment to dynamic trend prediction, improving the adaptability of personalized treatment plans.

The present invention relates to a non-invasive test for the detection of deep endometriosis. Particularly, although not exclusively, aspects of the present invention relate to one or more glycolysis-associated biomarkers (e.g., phosphoglycerate mutase 1 (PGAM1), Enolase-1 (ENO1), phosphofructokinase-1 (PFKP) and / or Hexokinase) and / or cytokines associated with aerobic glycolysis (e.g., IL-6 and / or TGF-β) which can be used to determine the likelihood of a subject having deep endometriosis based on a sample obtained from the subject.

A method comprising the steps of: (a) assessing an expression level of at least one protein, selected from the list consisting of: hemoglobin subunit beta and inter-alpha-trypsin inhibitor light chain, in a sample from a subject, and (b) using the expression level to determine whether the subject has endometriosis.

The invention relates to application of MEIS1 in preparation of an endometriosis therapeutic agent and the therapeutic agent prepared by the MEIS1. According to the invention, the influence of MEIS1 on an endometrial stromal cell apoptosis pathway is studied, endometrial stromal cell apoptosis is induced by overexpression of MEIS1 in endometrial stromal cells, and an MEIS1 lentivirus overexpression vector is used for administration to an endometriosis mouse model, so that the size and weight of a mouse endometriosis focus are remarkably reduced, and the application of MEIS1 in the endometriosis mouse model is realized. Liver and kidney biochemical indexes show that the LV-MEIS1 does not damage main organ functions and brings a new potential hope for treatment of endometriosis.

The present invention relates to a composition comprising eptinezumab and LuAG09222. This composition may be used, for example, to treat or prevent headache, pain, migraine, cluster headache, or endometriosis.

The present invention relates to a conjugate comprising a FAP targeting ligand and an effector for use in the treatment and / or diagnosis of endometriosis, as well as associated methods and kits.

The present invention relates to an integrated diagnostic system for deep endometriosis and / or adenomyosis, comprising three interconnected platforms and a method for analysing images generated by algorithms. The first platform combines patient medical history data with transvaginal ultrasound and / or pelvic magnetic resonance images, using algorithms to generate clear and detailed images of lesions. The method for analysing these images includes pre-processing, merging of clinical data and images, lesion identification, and comparison with a clinical database, resulting in a visual and descriptive analysis of the lesions, facilitating early and assertive diagnosis. The second platform is a communication network among specialist physicians, who perform a second reading of the images and issue a validated final report. The third platform is educational, offering personalised training and mentoring for imaging physicians using the images generated by the first platform to improve their diagnostic skills. The system reduces diagnostic time, increases accuracy, and contributes to the continuous professional development of physicians involved in the management of deep endometriosis and / or adenomyosis.

The present disclosure relates to methods and kits for detecting levels of androgens, androgen precursors and androgen metabolites. In particular, the present disclosure relates to methods and kits for diagnosing and / or prognosing endometriosis based on the levels of these androgens, androgen precursors and androgen metabolites.

A device, system and methods for the non-thermal treatment of endometriosis.

The sustained-release formulation of this invention, with its increased initial release, exhibits a rapid release effect within 24 hours after administration, followed by a sustained-release effect, thus simultaneously achieving both prolonged efficacy and rapid initial release. The sustained-release formulation of this invention, containing microspheres of leuprorelin, possesses excellent bioavailability and has been proven safe in humans; therefore, it can be effectively and safely used to treat various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine fibroids, prostate cancer, premenopausal breast cancer, and central precocious puberty.

The application discloses a traditional Chinese medicine formula for treating endometriosis, which comprises the following components in the weight fractions: cassia twig 14-16 parts, five spirit fat 8-12 parts, raw safflower 4-8 parts, xiaosha 4-8 parts, blood 4-8 parts, leech 2-5 parts, white peony root 8-12 parts, ophiopogon 8-12 parts, uncaria 12-14 parts, amber 4-8 parts and licorice 4-8 parts. The application is innovatively combined with the combination of heart calming and liver regulating on the basis of the original Pingchongjiangni formula, that is, warming heart yang to calm the rushing qi, calming heart qi to lower the rushing qi, and calming liver qi to follow the rushing qi, so that the purpose of calming the rushing qi is achieved. The traditional Chinese medicine formula can not only effectively relieve the dysmenorrhea of the patients with endometriosis, but also improve the psychological state such as depression and anxiety, and still has certain curative effect after stopping the medicine for three months.

The invention relates to the technical field of traditional Chinese medicine, in particular to application of a traditional Chinese medicine composition in preparation of medicine for preventing and treating endometriosis, and the traditional Chinese medicine composition comprises spina gleditsiae, polygonum cuspidatum, dandelion, sargentgloryvine stem, codonopsis pilosula, chinaroot greenbrier, radix paeoniae rubra, salvia miltiorrhiza, lindera aggregata and corydalis tuber. Experimental results show that the number of writhing times of mice fed with the traditional Chinese medicine composition is remarkably reduced, the ectopic endometrial volume is remarkably reduced, and serum PGE2 and PGF2 alpha secretion is remarkably reduced, so that the traditional Chinese medicine composition has a good treatment effect on endometriosis.

Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a —COOH group or a —OH group; R3′ and R3″ represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group; R4 and R5 represent a hydrogen atom, a halogen atom, a —IMH2 group, a (C1-C3)alkyl group, a (C1-C3)alkoxy group, or a —OH group; or R4 and R5 together form an oxo group or R4 and R5 together form a ═NOCH3 group or a (C3-C5)cycloalkyl group; R7 represents a hydrogen atom, a methyl group, a —OH group or a fluorine atom; R6 represents a phenyl group, a fused phenyl group, a bicyclic group comprising 5 to 12 carbon atoms, a heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms, a cycloalkyl group comprising 3 to 7 carbon atoms, a (C3-C6) cycloalkyl (C1-C3) alkyl group, a 3 to 8 membered-heterocycloalkyl group, a (C1-C6)alkyl group or a phenyl (C1-C2) alkyl group; X represents —CH2—, —O— or —S—; Y represents —CH═, —N═ or —CR″═; R8 represents a (C1-C3) alkyl group, a halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; R9 represents a hydrogen atom or a fluorine atom; RIO and RIO′ represent a hydrogen atom or a fluorine atom; R11 represents a hydrogen atom a (C1-C3)alkyl group or a cyclopropyl group; n is 0, 1 or 2, and m is 0 or 1. Further disclosed are process for preparing the same, pharmaceutical compositions comprising them as well as said compounds of formula (I) for use as an inhibitor and degrader of estrogen receptors, in particular in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

The invention discloses an application of an NFE2L2 inhibitor in preparation of a medicine for inhibiting growth of an endometriosis focus. The NFE2L2 inhibitor is ML385. It is proved for the first time that expression of the NFE2L2 in different types of endometriosis focuses (endometriosis focuses, ovarian endometriosis focuses and deep endometriosis focuses) is increased, and inhibition of the NFE2L2 can reduce the resistance of cells to an oxidative stress environment, increase ferroptosis sensitivity and reduce the viability of the cells; by applying the ML385, the growth of an endometriosis focus can be obviously inhibited, and a new treatment strategy is provided for treating the endometriosis.

The invention belongs to the technical field of bioengineering, and provides a drug-loaded targeted nano platform for targeted delivery of ZIF-8 drug-loaded nanoparticles by macrophages, a preparation method and an application, aiming at the technical problem that complications are easily caused by the existing treatment means of endometriosis, so that the invention provides a drug-loaded targeted nano platform for targeted delivery of ZIF-8 drug-loaded nanoparticles by macrophages, and a preparation method and application of the drug-loaded targeted nano platform. According to the invention, the ZIF-8 nano-particles and the drugs aiming at the energy metabolism level are combined to be used as the carrier, so that endometriosis cells with acidic cell microenvironment can be targeted, drug controlled release can be realized in the acidic environment of lesions, and the effective uptake of the endometriosis cells to the drugs is enhanced, thereby effectively increasing the uptake rate and the drug concentration at the target position, and improving the curative effect of the drug on the endometriosis cells. Meanwhile, the distribution of the medicine in normal tissues or cells is reduced, and the toxic and side effects of the medicine are reduced; and through the design of combining the macrophages with the ZIF-8 nano-particle carrier, the drug targeting property of the ZIF-8 nano-particle carrier can be obviously improved.

The invention provides a nucleic acid aptamer specifically combined with endometriosis cells and application of the nucleic acid aptamer, and belongs to the technical field of biology. The nucleic acid aptamer capable of being specifically combined with the endometriosis cells is screened out through the Cell-SELEX technology with living cells as screening objects, and the nucleic acid aptamer has the advantages of being high in specificity, high in affinity, high in specificity, high in specificity and high in specificity. The probe can be used for early diagnosis of endometriosis, tissue biopsy, ectopic endometrial tissue excision guided by fluorescence, targeted drug development and the like.

The present invention relates to levonorgestrel for use in a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 µg / day to about 100 µg / day. The invention further relates to levonorgestrel for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and / or dysmenorrhea comprising continuously administering about 60 µg / day to about 160 µg / day of levonorgestrel. Delivery devices, preferably, intravaginal rings for putting the methods in practice are also envisaged.

The invention discloses a system for endometriosis diagnosis and a computer storage medium. Aiming at major adjustment of endometriosis diagnosis standards, biomarkers and ploidy information of circulating endometrial cells in easily available samples such as peripheral blood of a patient are detected, and comprehensive risk assessment is performed by utilizing an optimization algorithm model, so that the diagnosis accuracy of endometriosis is improved. The invention provides an objective and quantifiable noninvasive diagnostic tool adapted to the adjusted standard, and the method solves the problem of missed diagnosis caused by false negative in the existing surgical diagnostic method, and has important clinical application value, social benefit and market prospect for improving the overall diagnostic level of endometriosis.